Reprogramming innate immunity to overcome endocrine resistance in estrogen receptor‐positive breast cancer

Documenti analoghi

• Exploring Terpenoids as Dual‐Action Agents in Diabetes and Cancer: A Review of Their Anti‐Hyperglycemic, Anti‐Glycolytic Actions, and Combination Therapy Potential
  di: Siti Nur Hasyila Muhammad, et al.
  Pubblicazione: (2026)
• Trends in breast cancer incidence by estrogen receptor status in the United States , 2004–2020
  di: Chenxi Jiang, et al.
  Pubblicazione: (2024)
• Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study
  di: Layla Andour, et al.
  Pubblicazione: (2025)
• Estrogen, estrogen receptor and the tumor microenvironment of NSCLC
  di: Mingxin Diao, et al.
  Pubblicazione: (2025)
• Terpenoids: Unlocking Their Potential on Cancer Glucose Metabolism
  di: Siti Nur Hasyila Muhammad, et al.
  Pubblicazione: (2024)